HTEC vs IHI

Key Takeaways

• HTEC offers global exposure to healthcare technology innovators like genomics and diagnostics firms, while IHI focuses on U.S. medical device manufacturers, providing more established large-cap names.
• HTEC's expense ratio of 0.68% is higher than IHI's 0.38%, reflecting its thematic indexing approach versus IHI's broad sector tracking.
• Both ETFs are passive but HTEC holds around 60 stocks with top 10 at ~23% concentration; IHI has ~47 holdings with top 10 comprising over 75%.
• HTEC exhibits higher volatility due to smaller, growth-oriented holdings, contrasting IHI's relatively stable profile tied to mega-cap leaders.
• In recent market cycles, HTEC has shown resilience in innovation-driven rallies, while IHI benefits from procedural volume recovery.
• HTEC's quarterly rebalancing captures emerging healthcare tech trends; IHI aligns with standard sector index methodology.

Introduction

HTEC and IHI represent complementary strategies within the burgeoning healthcare sector, where technological innovation meets essential medical infrastructure. HTEC targets global healthcare technology disruptors, emphasizing AI, genomics, and precision medicine, while IHI provides concentrated U.S. exposure to medical device giants driving surgical and diagnostic advancements. Investors compare them amid rising demand for advanced therapies, aging demographics, and AI integration in care delivery. Though not direct competitors, both ETFs appeal to those seeking defensive growth in healthcare, differing in geographic scope, company maturity, and innovation focus. This analysis highlights structural variances to inform sector allocation decisions in an environment of regulatory evolution and capital rotation toward health tech.

ROBO Global Healthcare Technology and Innovation ETF (HTEC) Overview

The ROBO Global Healthcare Technology and Innovation ETF (HTEC) is a passive, index-tracking ETF that seeks to replicate the ROBO Global Healthcare Technology and Innovation Index. Launched in June 2019, it invests at least 80% of assets in securities from this proprietary index, which selects 50-100 global companies deriving significant revenue from healthcare technology innovations like diagnostics, robotics, genomics, and AI-driven solutions. The fund holds approximately 59-61 stocks, with the top 10 comprising about 23% of assets. Key holdings include AXGN (AxoGen, ~3%), ARWR (Arrowhead Pharmaceuticals, ~2.5%), TWST (Twist Bioscience, ~2.3%), NTRA (Natera, ~2.2%), and NVCR (NovoCure, ~2.2%). Sector allocation is heavily skewed to healthcare (98%+), with minor technology exposure. The expense ratio is 0.68% (net), and it rebalances quarterly to maintain thematic purity. HTEC's distinguishing feature is its "HTEC Score" methodology, scoring companies on innovation potential for targeted exposure to high-growth sub-themes.

iShares U.S. Medical Devices ETF (IHI) Overview

The iShares U.S. Medical Devices ETF (IHI) is a passive ETF tracking the Dow Jones U.S. Select Medical Equipment Index, launched in May 2006. It focuses on U.S. companies manufacturing and distributing non-disposable medical devices, such as imaging scanners, prosthetics, pacemakers, and surgical tools. With around 47 holdings, it is highly concentrated, as the top 10 account for over 75% of assets. Prominent positions feature ISRG (Intuitive Surgical, ~16.7%), ABT (Abbott Laboratories, ~15.7%), SYK (Stryker, ~10.5%), EW (Edwards Lifesciences, ~5%), and BSX (Boston Scientific, ~4-5%). Allocation is 100% healthcare. The expense ratio stands at 0.38%, with quarterly distributions and low turnover (~16%). IHI's market-cap weighting favors established leaders, offering liquidity and stability in the devices subsector, bolstered by high daily volumes and tight spreads.

Industry and Thematic Backdrop

The healthcare technology and medical devices sectors are propelled by AI integration, robotics expansion, and precision medicine amid aging populations and rising chronic disease prevalence. Catalysts include AI-enhanced diagnostics, surgical robotics growth (projected multi-billion market), and real-world evidence for regulatory approvals. Capital flows favor innovation, with trends like telemedicine, wearables, and genomic sequencing driving demand. Macro drivers encompass post-pandemic procedural backlogs, favorable demographics, and tech convergence. Regulatory developments, such as FDA AI device clearances and quality standard harmonization (e.g., ISO 13485), support adoption but introduce scrutiny. Risks involve reimbursement pressures, supply chain vulnerabilities, cybersecurity threats to connected devices, and investor-driven rushed AI launches leading to recalls. Sector rotation toward defensives persists amid economic uncertainty, positioning both ETFs for macro tailwinds.

Performance and Positioning Comparison

In recent weeks and months, HTEC has demonstrated relative outperformance, with YTD declines around -5% versus IHI's steeper -19% to -21% drop, amid sector pressures from softer procedural demand and valuation resets in mega-caps. Over the past year, HTEC delivered ~25-27% returns, buoyed by innovation momentum in genomics and diagnostics, contrasting IHI's -14% to -19% amid healthcare rotation and hospital spending caution. HTEC's positioning benefits from global diversification and smaller-cap agility during AI-health tech rallies, though with elevated volatility. IHI's concentration in stable giants like ISRG provides downside cushion in risk-off environments but exposes it to top-holding earnings cycles. Interest rate expectations favor growth themes in HTEC, while IHI aligns with volume recovery; both exhibit beta above 0.9, with HTEC's higher turnover (~35%) aiding trend capture.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization (market cap), technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, empowering data-driven decisions across asset classes. Explore it today to uncover hidden gems in healthcare ETFs like HTEC and IHI.

Tickeron AI Verdict

Tickeron’s AI currently favors HTEC for its global thematic exposure to high-growth healthcare innovation, superior recent relative performance, and quarterly rebalancing capturing AI and genomics momentum. While IHI offers cost efficiency and liquidity, HTEC's diversification profile and trend consistency position it probabilistically stronger amid sector tailwinds, albeit with higher risk and fees. This assessment reflects observable structural advantages, not advice.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations